Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC148 + CAPEOX vs Bevacizumab + Chemotherapy in First-Line Advanced Colorectal Cancer
NCT07462143Phase 3Recruiting
- Sponsor
- RemeGen
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of RC148 in colorectal cancer (CRC), sponsored by RemeGen. Started May 2026; status: recruiting.
02
Drugs
RC148
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07462143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07462143.